All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Programmed cell death protein 1, also known as PD-1 and CD279 (cluster of differentiation 279), is a cell surface receptor that plays an important role in down-regulating the immune system and promoting self tolerance by suppressing T cell inflammatory activity. PD-1 is an immune checkpoint and guards against autoimmunity through a dual mechanism of promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (anti-inflammatory, suppressive T cells). PD-L1, the ligand for PD1, is highly expressed in several cancers and hence the role of PD1 in cancer immune evasion is well established. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer. Many tumor cells express PD-L1, an immunosuppressive PD-1 ligand; inhibition of the interaction between PD-1 and PD-L1 can enhance T-cell responses in vitro and mediate preclinical antitumor activity. This is known as immune checkpoint blockade. A number of cancer immunotherapy agents that target the PD-1 receptor have been developed. One such anti-PD-1 antibody drug, nivolumab, (Opdivo - Bristol Myers Squibb), produced complete or partial responses in non-small-cell lung cancer, melanoma, and renal-cell cancer, in a clinical trial with a total of 296 patients
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
XS-1022-ZP346 | Anti-PD-1 (NB01a) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | NB01a | Mouse | scFv-CD28-CD61ζ | Lentiviral vector | T cell | ||
XS-1022-ZP347 | Anti-PD-1 (MHC728) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | MHC728 | Mouse | scFv-41BB-CD60ζ | Lentiviral vector | T cell | ||
XS-1022-ZP348 | Anti-PD-1 (MHC728) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | MHC728 | Mouse | scFv-CD28-CD60ζ | Lentiviral vector | T cell | ||
XS-1022-ZP349 | Anti-PD-1 (DFPD1-12) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | DFPD1-12 | Human | scFv-41BB-CD61ζ | Lentiviral vector | T cell | ||
XS-1022-ZP350 | Anti-PD-1 (DFPD1-12) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | DFPD1-12 | Human | scFv-CD28-CD61ζ | Lentiviral vector | T cell | ||
XS-1022-ZP351 | Anti-PD-1 (273_C12_C05) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 273_C12_C05 | Human | scFv-41BB-CD62ζ | Lentiviral vector | T cell | ||
XS-1022-ZP353 | Anti-PD-1 (MW11-h317) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | MW11-h317 | Human | scFv-41BB-CD61ζ | Lentiviral vector | T cell | ||
XS-1022-ZP354 | Anti-PD-1 (MW11-h317) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | MW11-h317 | Human | scFv-CD28-CD61ζ | Lentiviral vector | T cell | ||
XS-1022-ZP355 | Anti-PD-1 (BAP049-Clone-E) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | BAP049-Clone-E | Human | scFv-41BB-CD62ζ | Lentiviral vector | T cell | ||
XS-1022-ZP356 | Anti-PD-1 (BAP049-Clone-E) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | BAP049-Clone-E | Human | scFv-CD28-CD62ζ | Lentiviral vector | T cell | ||
XS-1022-ZP357 | Anti-PD-1 (BA08-1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | BA08-1 | Human | scFv-41BB-CD63ζ | Lentiviral vector | T cell | ||
XS-1022-ZP358 | Anti-PD-1 (BA08-1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | BA08-1 | Human | scFv-CD28-CD63ζ | Lentiviral vector | T cell | ||
XS-1022-ZP359 | Anti-PD-1 (12760.15375) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 12760.15375 | Humanized | scFv-41BB-CD62ζ | Lentiviral vector | T cell | ||
XS-1022-ZP360 | Anti-PD-1 (12760.15375) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 12760.15375 | Humanized | scFv-CD28-CD62ζ | Lentiviral vector | T cell | ||
XS-1022-ZP361 | Anti-PD-1 (ch1B8) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | ch1B8 | Chimeric | scFv-41BB-CD63ζ | Lentiviral vector | T cell | ||
XS-1022-ZP362 | Anti-PD-1 (ch1B8) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | ch1B8 | Chimeric | scFv-CD28-CD63ζ | Lentiviral vector | T cell | ||
XS-1022-ZP363 | Anti-PD-1 (6F5H2L2) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 6F5H2L2 | Humanized | scFv-41BB-CD64ζ | Lentiviral vector | T cell | ||
XS-1022-ZP364 | Anti-PD-1 (6F5H2L2) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 6F5H2L2 | Humanized | scFv-CD28-CD64ζ | Lentiviral vector | T cell | ||
XS-1022-ZP365 | Anti-PD-1 (hPDl-A) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | hPDl-A | Humanized | scFv-41BB-CD63ζ | Lentiviral vector | T cell | ||
XS-1022-ZP409 | Anti-PD-1 (h409A11) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | h409A11 | Humanized | scFv-41BB-CD71ζ | Lentiviral vector | T cell | ||
XS-0823-LX82 | Anti-hPD-1 (AB) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector | Human | AB | Adenoviral vectors |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION